Peter M. Voorhees, MD, shares key insights from the 2025 American Society of Clinical Oncology Annual Meeting, specifically in the multiple myeloma space.

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Multiple myeloma, a treatable but incurable blood cancer, is rising sharply in India, especially among those over 60. Dr.

A new form of immunotherapy is showing promising results for multiple myeloma patients in a study, an investigation found that crime-free lease addendums aren't reducing crime and increasing ...

Multiple myeloma bone lesions occur when cancerous cells cause the bones to form weak spots, which can lead to breaks. Learn more about lesions and pain.

This case highlights the need for immunohistochemical profiling of patients with multiple breast nodules and a history of refractory myeloma.

A groundbreaking new therapy for multiple myeloma nearly triples disease-free survival, as NICE recommends belantamab mafodotin in a world-first move. Learn how this treatment could benefit 1,500 ...